# Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors

> **NCT04234113** · PHASE1 · TERMINATED · sponsor: **SOTIO Biotech AG** · enrollment: 115 (actual)

## Conditions studied

- Thyroid Cancer
- Renal Cell Carcinoma
- Non Small Cell Lung Cancer
- Small-cell Lung Cancer
- Bladder Cancer
- Melanoma
- Merkel Cell Carcinoma
- Skin Squamous Cell Carcinoma
- Microsatellite Instability High
- Triple Negative Breast Cancer
- Mesothelioma
- Thymic Cancer
- Cervical Cancer
- Biliary Tract Cancer
- Hepatocellular Carcinoma
- Ovarian Cancer
- Gastric Cancer
- Head and Neck Squamous Cell Carcinoma
- Anal Cancer

## Interventions

- **DRUG:** Nanrilkefusp alfa
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT04234113
- **Lead sponsor:** SOTIO Biotech AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-06-13
- **Primary completion:** 2024-08-31
- **Final completion:** 2024-11-27
- **Target enrollment:** 115 (ACTUAL)
- **Why stopped:** Due to lack of efficacy shown at the time of the interim analysis.
- **Last updated:** 2026-03-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04234113

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04234113, "Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04234113. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*